LC-Fatty Acid Oxidation Disorders: Recent Updates on the REN001 Study

There was much discussion about current research in FAODs at our recent International Metabolic conference last month. Reneo Pharmaceuticals recently released positive results from the REN001 Phase1b LC-FAOD Study.

Please join us for an update on the Reneo LC-FAOD study. Dr. Alex Dorenbaum, Chief Medical Officer at Reneo Pharmaceuticals will provide background about this clinical study and will answer your questions.

Related Events

• 

  2024 Energy Walk & 5k – Syracuse

  September 15 @ 9:00 am – 1:00 pm
• 

  Energy Walk – Boston

  September 20 @ 5:00 pm – 9:00 pm
• 

  Mito Town Meeting

  January 10, 2025 @ 12:00 am